
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Analgesic nephropathy historical perspective
Introduction
Overview
Overview
In 1953, the association between analgesic drugs and chronic renal disease was first reported in German. In 1977, Australia was first to legally ban phenacetin. In 1983, phenacetin was withdrawn from the US markets.
Historical Perspective
Historical Perspective
- In 1887, phenacetin was introduced as an analgesic which later became know that is metabolized to acetaminophen.[1]
- In 1893, acetaminophen was introduced as an analgesic.[1]
- In 1953, the association between analgesic drugs and chronic renal disease was first reported in German.[2]
- In 1977, phenacetin became legally banned in Australia.[3] Β
- In 1978, phenacetin was withdrawn from the Canadian markets.[4]
- In 1980, phenacetin was withdrawn from the markets in the United Kingdom.[4]
- In 1983, phenacetin was withdrawn from the US markets.[5]
References
References
- β 1.0 1.1 Foye, William (2008). Foye’s principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins. ISBNΒ 978-0-7817-6879-5. OCLCΒ 145942325.
- β SpΓΌhler O, Zollinger HU (1953). “Die chronisch-interstitielle Nephritis”. Z Klin Med (in German). 151 (1): 1β50. PMIDΒ 13137299.
- β Michielsen P, de Schepper P (2001). “Trends of analgesic nephropathy in two high-endemic regions with different legislation”. J. Am. Soc. Nephrol. 12 (3): 550β6. PMIDΒ 11181803. Unknown parameter
|month=ignored (help) - β 4.0 4.1 “Some pharmaceutical drugs”. IARC Monogr Eval Carcinog Risk Chem Hum. 24: 1β337. 1980. PMIDΒ 6937434.
- β “List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule”. Fed Regist. 64 (44): 10944β7. 1999. PMIDΒ 10557618.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
